ARKG Holdings of CERS
Cerus Corporation
CERS, or Cerus Corporation, specializes in developing and commercializing innovative blood transfusion technologies designed to enhance the safety of blood transfusions by inactivating pathogens in blood components. The company generates revenue through the sale and distribution of its INTERCEPT Blood System, particularly in markets requiring advanced blood safety solutions, such as Europe and the United States.
Trades of CERS in ARKG
The ten most recent trades of Cerus Corporation in the ARKG ETF.View all trades
Date | Direction | Market Value | % of Position | % of ETF |
|---|---|---|---|---|
| Oct 30, 2024 | Buy | $277,642 | 2.25% | 0.02% |
| Oct 29, 2024 | Buy | $91,419 | 0.74% | 0.01% |
| Oct 28, 2024 | Buy | $82,070 | 0.67% | 0.01% |
| Oct 25, 2024 | Buy | $229,928 | 1.98% | 0.02% |
| Oct 24, 2024 | Buy | $92,409 | 0.81% | 0.01% |
| Oct 22, 2024 | Buy | $123,780 | 1.10% | 0.01% |
| Oct 21, 2024 | Buy | $77,279 | 0.68% | 0.01% |
| Oct 18, 2024 | Buy | $69,389 | 0.63% | 0.01% |
| Mar 22, 2024 | Buy | $504,762 | 3.31% | 0.03% |
| Mar 21, 2024 | Buy | $384,009 | 2.49% | 0.02% |